Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
9.27
0.00 (0.00%)
At close: Nov 19, 2025, 4:00 PM EST
9.14
-0.13 (-1.40%)
After-hours: Nov 19, 2025, 5:42 PM EST
Verastem Revenue
Verastem had revenue of $11.24M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $13.38M, up 33.79% year-over-year. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$13.38M
Revenue Growth
+33.79%
P/S Ratio
42.00
Revenue / Employee
$171,526
Employees
78
Market Cap
715.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VSTM News
- 5 days ago - Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 6 days ago - Verastem Oncology Announces Proposed Public Offering of Common Stock - Business Wire
- 14 days ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire
- 15 days ago - Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 27 days ago - Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Business Wire
- 27 days ago - Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire
- 4 weeks ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma - Business Wire